
Sign up to save your podcasts
Or


Dr. Robin Hofmann is an assistant professor for criminal law and criminology at Maastricht University, Alfredo Pascual is Vice-President of Investment Analysis at Seed Innovations, a European Cannabis VC.
They are both leading experts in the area of international cannabis policy and regulation. Together with Moritz Förster, chief editor of krautinvest.de, they discuss how Germany will make the magic happen: Legalize adult-use cannabis in a very complex international regulative environment.
You will get answers to questions such as:
How will enforcement look like in the EU?
How would a legislative procedure in the EU look like?
What are the Germany's chances and arguments when the European Cour of Justice would need to make a decision?
What would the timeline be if Germany decides to leave and re-enter the Single Convention? What are the risks?
How realistic is a inter se modification with other countries? What are the obstacles?
Is a scientific approach the way to go? And what are the criteria for a scientific adult use market?
By Moritz Förster c/o krautinvest.deDr. Robin Hofmann is an assistant professor for criminal law and criminology at Maastricht University, Alfredo Pascual is Vice-President of Investment Analysis at Seed Innovations, a European Cannabis VC.
They are both leading experts in the area of international cannabis policy and regulation. Together with Moritz Förster, chief editor of krautinvest.de, they discuss how Germany will make the magic happen: Legalize adult-use cannabis in a very complex international regulative environment.
You will get answers to questions such as:
How will enforcement look like in the EU?
How would a legislative procedure in the EU look like?
What are the Germany's chances and arguments when the European Cour of Justice would need to make a decision?
What would the timeline be if Germany decides to leave and re-enter the Single Convention? What are the risks?
How realistic is a inter se modification with other countries? What are the obstacles?
Is a scientific approach the way to go? And what are the criteria for a scientific adult use market?